Health Technology Takeda Pharmaceutical Co., Ltd. Business Summary
Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.
Financial Highlights
Mar 2020
JPY USD Revenue 3,291.18B 30,270.54M Gross Profit 1,789.37B 16,457.72M Operating income 302,612M 2,783.25M Income before tax -60,754M -558.78M Net income 44,241M 406.90M EBITDA 886,261M 8,151.34M Diluted EPS 28.24 0.25 Dividends Per Share 180 1.65 Total Assets 12,821.09B 118,763.31M Total liabilities 8,093.60B 74,972.05M Total equity 4,723.48B 43,754.18M Operating cash flow 555,410M 5,108.35M Currency in JPY Currency in USD
Historical Data Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Revenue
1,807.37B
1,732.05B
1,770.53B
2,097.22B
3,291.18B
Gross Profit
1,161.84B
1,017.65B
1,148.86B
1,275.55B
1,789.37B
Operating income
175,770M
86,972M
195,320M
218,686M
302,612M
Income before tax
120,539M
143,346M
217,205M
127,612M
-60,754M
Net income
80,166M
114,940M
186,886M
135,192M
44,241M
EBITDA
353,275M
258,398M
377,447M
466,377M
886,261M
Diluted EPS
101.71
146.25
237.55
139.82
28.24
Dividends Per Share
180
180
180
180
180
Total Assets
3,824.08B
4,346.79B
4,106.46B
13,792.77B
12,821.09B
Total liabilities
1,812.88B
2,397.82B
2,089.05B
8,606.78B
8,093.60B
Total equity
1,948.69B
1,894.26B
1,997.42B
5,181.98B
4,723.48B
Operating cash flow
26,552M
260,067M
379,600M
302,609M
555,410M
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Revenue
15,050.91M
15,994.93M
15,974.84M
18,911.85M
30,270.54M
Gross Profit
9,675.22M
9,397.74M
10,365.80M
11,502.42M
16,457.72M
Operating income
1,463.72M
803.15M
1,762.30M
1,972.01M
2,783.25M
Income before tax
1,003.78M
1,323.75M
1,959.76M
1,150.74M
-558.78M
Net income
667.58M
1,061.43M
1,686.20M
1,219.10M
406.90M
EBITDA
2,941.89M
2,386.22M
3,405.56M
4,205.58M
8,151.34M
Diluted EPS
0.84
1.35
2.14
1.26
0.25
Dividends Per Share
1.49
1.66
1.62
1.62
1.65
Total Assets
34,023.62M
39,009.18M
38,612.71M
124,612.85M
118,763.31M
Total liabilities
16,129.56M
21,518.70M
19,643.19M
77,759.25M
74,972.05M
Total equity
17,337.88M
16,999.56M
18,781.60M
46,817.41M
43,754.18M
Operating cash flow
221.11M
2,401.63M
3,424.99M
2,728.79M
5,108.35M
Valuation Measures
Mar 2020
PER 116.43 ROA 0.33% ROE 0.89% Operating margin 9.19% Profit margin 1.34%
Key executives
President, CEO & Representative Director:
Christophe Weber
Chief Financial Officer & Director:
Constantine Saroukos
Director, Research & Development President:
Andrew S. Plump
Chief Medical & Scientific Officer:
Michael E. Mendelsohn
Chief Ethics & Compliance Officer:
Mwana Lugogo Shareholders
Nomura Asset Management Co., Ltd. (3.9%)
Sumitomo Mitsui Trust Asset Management Co., Ltd. (3.3%)
The Vanguard Group, Inc. (2.6%)
Nippon Life Insurance Co. (2.2%)
Daiwa Asset Management Co. Ltd. (1.8%)
Nikko Asset Management Co., Ltd. (1.5%)
BlackRock Fund Advisors (1.5%)
Norges Bank Investment Management (1.5%)
Capital Research & Management Co. (World Investors) (0.8%)
Mitsubishi UFJ Kokusai Asset Management Co., Ltd. (0.8%)
Related Companies
Takeda Dunboyne Biologics Ltd.
Takeda Pharmaceutical Co. Ltd. /Europe OTC Portfolio/
Plasmaspendedienst GmbH
Gaido Health, Inc.
Takeda Pharmaceutical Co. Ltd. /Non Core Latin America Assets/
Takeda Pharmaceutical Co. Ltd. /Non Core Assets/
Takeda Re Insurance AG
Takeda Pharmaceutical Co. Ltd. /Tachosil Business/
Plasmapunkt Favoriten GmbH
Takeda Malaysia Sdn. Bhd.
Takeda Pharmaceutical Co. Ltd. /Latam Bus/
Takeda Oranienburg Real Estate GmbH & Co. KG
Takeda Consumer Healthcare Co., Ltd.
Pvp Biologics, Inc.
Takeda Pharmaceutical Director Incentive Plan
Takeda Pharmaceutical Employee Incentive Plan
Oy Leiras Takeda Pharmaceuticals AB
Takeda Architectural Design Consulting (Shanghai) Co. Ltd.
Takeda Pharma AB
Takeda Development Center Americas, Inc.
Takeda Ukraine LLC
Takeda Pharmaceuticals Taiwan Ltd.
Takeda SRL
Takeda Hellas SA
Takeda Christiaens SCA/CVA
Takeda Belgium SCA/CVA
Takeda Vaccines Pte Ltd.
Takeda Pharmaceuticals (Asia Pacific) Pte Ltd.
Takeda Development Center Asia Pte Ltd.
Takeda Pharma Sp zoo
Competitors
AstraZeneca PLC
Grifols, S.A. Class A
Amgen Inc.
Roche Holding AG
Amicus Therapeutics, Inc.
Protalix Biotherapeutics, Inc.
Novartis AG
Sanofi
Pfizer Inc.
Merck & Co., Inc.
AbbVie, Inc.
Johnson & Johnson
CSL Limited
Bristol-Myers Squibb Company
Bayer AG
Biotest AG Pref
UCB S.A.
Merck KGaA
Swedish Orphan Biovitrum AB
Novo Nordisk A/S Class B
ISU Abxis Co., Ltd.
Emmaus Life Sciences, Inc.
Dr. Reddy's Laboratories Ltd.
Hypera S.A.
Ipsen SA
Eli Lilly and Company
Green Cross Holdings Corporation
Daewoong Co., Ltd.
BeiGene, Ltd.
Hanmi Pharmaceutical Co., Ltd.
Copyright © 2020 FactSet Research Systems Inc. All rights reserved.
Last Updated on 24 Nov, 2020
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.
Celebrate our next chapter Find out more
By continuing to browse this website, you accept cookies which are used for several reasons such as personalizing content/ads and analyzing how this website is used. Please review our
Cookie Policy
to learn how you can update your cookie settings.
Accept & Continue
Close
